标签归档：kki

KKI-5 (TFA)

发表于由

KKI-5 (TFA); 纯度: 99.93%

KKI-5 (TFA) 是一种特异性的组织激肽释放酶 (kallikrein) 抑制剂。KKI-5 (TFA) 可降低乳腺癌细胞浸润。

KKI-5 (TFA)amp;;

KKI-5 (TFA) Chemical Structure

规格 价格 是否有货 数量
1 mg ￥750 In-stock
5 mg ￥2250 In-stock
10 mg ￥3950 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

KKI-5 (TFA) 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion[1].

IC50 Target

Kallikrein[1]
分子量

887.90

Formula

C37H56F3N11O11
Sequence

Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2
Sequence Shortening

Ac-PFRSVQ-NH2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro:;

H2O : 9.09 mg/mL (10.24 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1263 mL 5.6313 mL 11.2625 mL
5 mM 0.2253 mL 1.1263 mL 2.2525 mL
10 mM 0.1126 mL 0.5631 mL 1.1263 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Deshpande MS, et al. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392. J Med Chem. 1992 Aug 21;35(17):3094-102.

KKI-5(Synonyms: 激肽释放酶抑制剂)

发表于由

KKI-5;(Synonyms: 激肽释放酶抑制剂)

KKI-5 是一种特异性的组织激肽释放酶 (kallikrein) 抑制剂。KKI-5 可降低乳腺癌细胞浸润。

KKI-5amp;;(Synonyms: 激肽释放酶抑制剂)

KKI-5 Chemical Structure

CAS No. : 97145-43-2

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

KKI-5 的其他形式现货产品:

KKI-5 (TFA)

生物活性

KKI-5 is a specific inhibitor of tissue kallikrein. KKI-5 can attenuate breast cancer cell invasion[1].

IC50 Target

Kallikrein Inhibitor
体外研究
(In Vitro)

The KKI-5 Peptide corresponds to aa386-391 of bovine kininogen-1 that encompasses the aa388-389 kallikrein proteolytic site. The synthetic KKI-5 can attenuate breast cancer cell invasion, therefore it is investigated for its role in invasion and metastasis of cancer cells.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

773.88

Formula

C35H55N11O9
CAS 号

97145-43-2
Sequence

Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2
Sequence Shortening

Ac-PFRSVQ-NH2
中文名称

激肽释放酶抑制剂
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Deshpande MS, et al. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392. J Med Chem. 1992 Aug 21;35(17):3094-102.